Impact of everolimus-related interstitial lung disease on subsequent treatment in patients with metastatic breast cancer
e-rILD may not influence the choice of following treatment or the development of drug-related ILD during subsequent treatments.
Authors
- Kenichi Harano (ORCID: https://orcid.org/0000-0002-0833-3489)
- Nobuaki Matsubara (ORCID: https://orcid.org/0000-0002-9203-4245)
- Naoki Niikura (ORCID: https://orcid.org/0000-0001-6732-8527)
- Shota Kusuhara
- Hikari Kiyohara
- Misao Fukuda (ORCID: https://orcid.org/0009-0000-7720-3875)
- Chikako Funasaka (ORCID: https://orcid.org/0000-0003-0585-4884)
- Yoichi Naito (ORCID: https://orcid.org/0000-0002-8490-9064)
- Chihiro Kondoh (ORCID: https://orcid.org/0000-0001-6189-4851)
- Akira Hirota (ORCID: https://orcid.org/0000-0003-3301-089X)
- Ako Hosono
- N. Takahashi
- Hiromichi Nakajima
- Toru Mukohara
- Takehiko Nakao
Institutions
- Tokai University (JP)
- Saitama Cancer Center (JP)
- National Cancer Center Hospital East (JP)
Publication Details
- Journal
- The Oncologist
- Published
- 2026-03-08
- DOI
- https://doi.org/10.1093/oncolo/oyag082
- Primary Topic
- PI3K/AKT/mTOR signaling in cancer
- Type
- article
- Field-Weighted Citation Impact
- 0.00